U.S. markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
54.17-0.91 (-1.65%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close55.08
Open54.97
Bid53.98 x 900
Ask55.00 x 900
Day's Range52.69 - 55.44
52 Week Range36.15 - 151.80
Volume399,898
Avg. Volume1,486,250
Market Cap10.088B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Financial Times

    ‘The race is on’: CureVac seeks answers to vaccine disappointment

    When the coronavirus pandemic struck, CureVac was supposed to be the first to bring a revolutionary vaccine technology to market. Now executives, investors and industry watchers are struggling to understand what went wrong — and whether the company must change its approach to the messenger ribonucleic acid technology it was so critical to advancing. CureVac’s troubles started not long after coronavirus began to spread.

  • Questor: our vaccine stocks are fine, but nothing can inoculate airlines against Covid uncertainty
    The Telegraph

    Questor: our vaccine stocks are fine, but nothing can inoculate airlines against Covid uncertainty

    Questor tipped four coronavirus vaccine makers between last August and this April and the black sheep of that family has been CureVac, the German-based but American-listed biotech firm. While shares in BioNTech, Moderna (which we later sold at a large profit) and AstraZeneca have all performed well, especially the former two, those in CureVac have lost more than half their value after it announced disappointing vaccine efficacy last month. Time to throw them into the sharps bin? Much of our inte

  • Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
    Motley Fool

    Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

    CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.